



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

JP

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/919,758	07/31/2001	Xiaowu Liang	57830.00007.CON	4879

36183 7590 06/14/2005

PAUL, HASTINGS, JANOFSKY & WALKER LLP  
P.O. BOX 919092  
SAN DIEGO, CA 92191-9092

EXAMINER

STRZELECKA, TERESA E

ART UNIT PAPER NUMBER

1637

DATE MAILED: 06/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 09/919,758	<b>Applicant(s)</b> LIANG ET AL.	
	<b>Examiner</b> Teresa E. Strzelecka	<b>Art Unit</b> 1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 29 April 2005.
- 2a) ☐ This action is FINAL.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-3,5-8,21-25,27-39,41 and 43-46 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3,5-8,21-25,27-39,41 and 43-46 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

5.00

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on April 29, 2005 has been entered.

2. Claims 1-3, 5-12, 14-25, 27-41 and 43-46 were previously pending. Applicants cancelled claims 9-12, 14-20 and 40, and amended claims 21, 25, 37, 39, 44 and 45. Claims 1-3, 5-8, 21-25, 27-39, 41 and 43-46 are pending and will be examined.

3. Applicants' claim amendments and cancellations obviated the following rejections: rejection of claims 9, 19, 25, 37 and 45 under 35 U.S.C. 112, first paragraph, written description; rejection of claims 10-12 and 14-16 under 35 U.S.C. 102(b) as anticipated by Shi et al.; rejection of claim 20 under 35 U.S.C. 103(a) over Shi et al. and Felgner et al.; rejection of claims 17 and 18 under 35 U.S.C. 103(a) over Shi et al. and Uhlman et al.; rejection of claims 7, 9, 17 and 19 under 35 U.S.C. 103(a) over Shi et al. and Goodchild; rejection of claim 40 under 35 U.S.C. 103(a) over Shi et al. and Mullis et al. All other rejections are maintained for reasons given in the "Response to Arguments" section below.

4. Applicants' amendment to specification obviated the new matter objection to specification.

### ***Response to Arguments***

5. Applicant's arguments filed April 29, 2005 have been fully considered but they are not persuasive. Only claims still pending will be discussed.

A) Regarding the rejection of claims 1, 2, 5, 6, 21, 22, 27-34 and 46 under 35 U.S.C. 102(b) as anticipated by Shi et al., Applicants argue the following:

a) The claims require first amplification step with two primers which add regions of complementarity to the ends of amplified fragment, followed by amplification with primers containing promoter and terminator sequences. Applicants argue that Shi et al. do not teach a terminator-containing primer in the first amplification step, since, as claimed by Applicants, "the terminator-containing sequence (primer 10 (BSH)) that contains the "BamHI cloning sites, and a pair of translational stop codons" does not contain a sequence that hybridizes to the same target sequence as that of the promoter containing sequence. Indeed, the BSH primer is used as the final primer in the amplification reaction (quoting page 49, first column of Shi)." Therefore, Applicants argue, the promoter-containing primer and the terminator-containing primer would have been added to "different" PCR fragments.

However, as can be seen from the paragraph of Shi et al. quoted by Applicants, this paragraph does not say anything at all which of the primers contains the termination codons. The first paragraph of page 47 states "the ninth oligonucleotide added two translational stop codons and a 3' restriction site". Therefore, both the promoter-containing primer 1 and terminator-containing primer 9 were present in the same reaction mixture.

b) Claim 21 requires intermediate nucleic acid fragment amplification with oligonucleotides conferring function, while Shi et al. teaches addition of a terminator-containing primer to a different nucleic acid molecule to which the promoter sequence is added.

This argument was addressed above. Further, the claim is drawn to addition of "functional nucleic acid regions". As can be seen from the last paragraph of page 46 and the first paragraph of page 47, each of the nine oligonucleotide primers used in the first PCR reaction contained

Art Unit: 1637

functional regions: restriction site for cloning, promoter, Shine/Dalgarno sequence, signal peptide sequence and coded for peptide linkers. Therefore, even if oligonucleotide 9 did not contain a terminator, claim 21 does not require the terminator or promoter, for that matter.

c) Claim 30 requires a 5' biological function conferring nucleic acid fragment and a 3' biological function conferring nucleic acid fragment, whereas Shi et al. do not teach primers which in addition to functional regions include region complementary to extension primers that each contain regions of complementarity to a target nucleic acid.

As indicated above, primers of Shi et al. contain regions which confer biological function (page 46, last paragraph, page 47, first paragraph). These primers had 16-21 nucleotide overlaps with the next strand produced by a set of primers, and 24- or 30-nucleotide overlap with the target sequences (page 49, third paragraph; Fig. 1). Therefore, Shi et al. teach all of the elements of claim 30.

The rejection is maintained.

B) Regarding the rejection of claims 3, 23 and 35 under 35 U.S.C. 103(a) over Shi et al. and Felgner et al., Applicants argue that since Shi et al. do not teach addition of promoter-containing and terminator-containing fragments to the same nucleic acid target, the rejection is improper.

The argument about Shi et al. teaching addition of promoter and terminator to the same sequence was addressed above.

The rejection is maintained.

C) Regarding the rejection of claims 7, 8, 24, 25, 36 and 37 under 35 U.S.C. 103(a) over Shi et al. and Uhlman et al., Applicants argue that since Shi et al. do not teach addition of promoter-containing and terminator-containing fragments to the same nucleic acid target, the rejection is improper.

The argument about Shi et al. teaching addition of promoter and terminator to the same sequence was addressed above. Further, claims 24, 25, 36 and 37 do not require addition of either promoter or terminator, therefore this argument is moot with respect to these claims.

The rejection is maintained.

D) Regarding the rejection of claims 38, 39, 41 and 43 under 35 U.S.C. 103(a) over Shi et al. and Mullis et al., Applicants argue that Shi et al. do not teach addition of promoter and terminator primers which would hybridize to the regions of complementarity on the same target DNA. However, claim 38 does not require promoter and terminator sequences, but “transcriptionally-functional regions”. Shi et al. teach primer 2 containing a Shine-Dalgarno sequence, primers 5 and 6 containing signal peptide sequences and primers 7 and 8 coding for linker peptides, which are all transcriptionally-functional regions (Table 2). As to multiplexing, amplification of multiple targets was known in the art, and, since the claim does not require that the reactions be performed in the same tube (and, in fact, claim 41 is drawn to amplification of different targets separately), it would be obvious to amplify several targets at once.

The rejection is maintained.

E) Regarding the rejection of claims 44 and 45 under 35 U.S.C. 103(a) over Shi et al., Mullis et al. and Uhlman et al., Applicants argue that Shi et al. do not teach addition of first and second functional sequences to target nucleic acid. The claim is drawn to addition of “region that confers function” to target nucleic acid. Shi et al. teach primer 1 containing a promoter, primer 2 containing a Shine-Dalgarno sequence, primers 5 and 6 containing signal peptide sequences and primers 7 and 8 coding for linker peptides, which are all region which confer function (Table 2).

The rejection is maintained.

***Claim Interpretation***

6. The term “nucleic acid sequence that confers function” has not been defined by Applicants, therefore it is interpreted as any nucleic acid sequence.
7. The term “transcriptionally functional region” has not been defined by Applicants, therefore it is interpreted as any sequence which is involved in transcription.

***Claim Rejections - 35 USC § 102***

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 1, 2, 5, 6, 21, 22, 27-34 and 46 are rejected under 35 U.S.C. 102(b) as being anticipated by Shi et al. (PCR Meth. Appl., vol. 3, pp. 46-53, 1993; cited in the previous office action).

Regarding claim 1, Shi et al. teach a method for amplifying a transcriptionally-active polynucleotide, comprising:

performing a first PCR amplification step to amplify a first fragment of DNA with a first primer pair, wherein the first primer pair, upon such amplification, adds to first and second ends of the first fragment predetermined first and second regions of complementarity, to form a second DNA fragment having said first region of complementarity at a first end and a second region of complementarity at a second end of said second DNA fragment (Shi et al. teach synthesis of human Lym-1 antibody gene by PCR from fourteen oligonucleotide fragments (page 46, fifth paragraph; page 47, first paragraph; Fig. 1). The two main fragments contained amplified V<sub>H</sub> and V<sub>L</sub> regions of the Lym-1 antibody, which were 615 or 522 bp and 422 bp in size, respectively (page 46, fifth

Art Unit: 1637

paragraph; page 47, third and fourth paragraphs; Fig. 1; page 50, second paragraph). Therefore, the  $V_H$  and  $V_L$  fragments were the targets for amplification (Fig. 1). In the first step of PCR, the two fragments were contacted with primers 1-9 (page 49, third paragraph; Fig. 1). As can be seen from Fig. 1, primers 7 and 9 add to the  $V_H$  fragment first and second regions of complementarity, which are complementary to regions of primers 8 and 10, primers 5 and 8 add to the  $V_L$  fragment first and second regions of complementarity, which are complementary to regions of primers 7 and 6, etc. Therefore, at any point during the amplification reaction, each fragment, is contacted sequentially with two primers, both of which contain regions of complementarity to which the next two primers anneal.);

providing a promoter-containing sequence and a terminator-containing sequence, said promoter-containing sequence further including a region complementary to said first region of complementarity, and said terminator-containing sequence further including a region complementary to said second region of complementarity, wherein both said promoter-containing sequence and said terminator-containing sequence include an internal nucleotide capable of forming an A-T base pair immediately adjacent to said region of complementarity (Shi et al. teach providing fragments containing the hybrid  $\lambda$  phage promoter sequence and terminator sequence (page 49, third paragraph). Both the first fragment and the tenth fragment contain nucleotides capable of forming an A-T base pair immediately adjacent to the regions of complementarity (Table 2; page 51, third paragraph.));

joining said promoter-containing sequence to said first end of said second DNA fragment and said terminator-containing sequence to said second end of said second DNA fragment to form said third DNA fragment (Shi et al. teach PCR amplifying the  $V_H$  and  $V_L$  fragments with fragments



Art Unit: 1637

1-9 which contain the promoter and terminator, therefore joining the promoter and terminator-containing fragments to fragments V<sub>H</sub> and V<sub>L</sub> (Fig. 1; page 49, third paragraph).); and

performing a second PCR amplification step to amplify said third DNA fragment (Shi et al. teach a second step PCR amplification of the whole gene using primers 2 and 10 (page 49, third paragraph; Fig. 1).).

Regarding claim 2, Shi et al. teach PCR amplifying the V<sub>H</sub> and V<sub>L</sub> fragments with fragments 1-9 which contain the promoter and terminator, therefore joining the promoter and terminator-containing fragments to fragments V<sub>H</sub> and V<sub>L</sub> (Fig. 1; page 49, third paragraph).

Regarding claims 5 and 6, Shi et al. teach Vent or Taq polymerase (page 49, fourth paragraph; page 50, first paragraph).

Regarding claim 21, Shi et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Shi et al. teach synthesis of human Lym-1 antibody gene by PCR from fourteen oligonucleotide fragments (page 46, fifth paragraph; page 47, first paragraph; Fig. 1). The two main fragments contained amplified V<sub>H</sub> and V<sub>L</sub> regions of the Lym-1 antibody, which were 615 or 522 bp and 422 bp in size, respectively (page 46, fifth paragraph; page 47, third and fourth paragraphs; Fig. 1; page 50, second paragraph). Therefore, the V<sub>H</sub> and V<sub>L</sub> fragments were the targets for amplification (Fig. 1). In the first step of PCR, the two fragments were contacted with primers 1-9 (page 49, third paragraph; Fig. 1). As can be seen from Fig. 1, primers 7

Art Unit: 1637

and 9 add to the  $V_H$  fragment first and second regions of complementarity, which are complementary to regions of primers 8 and 10, primers 5 and 8 add to the  $V_L$  fragment first and second regions of complementarity, which are complementary to regions of primers 7 and 6, etc. Therefore, at any point during the amplification reaction, each fragment, is contacted sequentially with two primers, both of which contain regions of complementarity to which the next two primers anneal.);

performing a first PCR amplification step comprising amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second extension regions (Shi et al. teach a first PCR amplification step using primers 1-9 (page 49, third paragraph; Fig. 1).);

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein each of said third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Shi et al. teach PCR amplifying the  $V_H$  and  $V_L$  fragments with fragments 1-9 which contain the promoter, a Shine/Dalgarno sequence, signal peptide, sequence encoding a peptide linker and terminator (= nucleic acid regions that confer function), therefore joining the function-conferring fragments to fragments  $V_H$  and  $V_L$  (Fig. 1; page 46, last paragraph; page 47, first paragraph; Table 2; page 49, third paragraph).); and

performing a second PCR amplification step comprising amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises more than one functional nucleic acid regions joined to the polynucleotide target sequence (Shi et al. teach a second step PCR amplification of the whole gene using primers 2

and 10, generating a nucleic acid containing functional nucleic acid regions (page 49, third paragraph; Fig. 1)).

Regarding claims 22 and 29, Shi et al. teach nucleic acid regions which comprise a promoter and a terminator (page 49, third paragraph).

Regarding claims 27 and 28, Shi et al. teach Vent or Taq polymerase (page 49, fourth paragraph).

Regarding claim 30, Shi et al. teach a reaction mixture (= system for adding a nucleic acid fragment that confers function to a polynucleotide sequence), comprising:

an extension primer pair, each primer of which comprises a region of complementarity to a strand of the polynucleotide target sequence and a predetermined extension region (Shi et al. teach a reaction mixture that contains the oligonucleotides with sequences complementary to the target sequence and extension regions, such as oligonucleotides 1-9 (extension primer pairs) (Fig. 1, page 49, third paragraph); and

a 5' biological function conferring nucleic acid fragment and a 3' biological function conferring nucleic acid fragment, each fragment of which comprises a region of complementarity to one of the extension regions, and a biological function conferring polynucleotide sequence that confers biological function, wherein the extension primer pairs are adapted to add the extension regions to a target sequence upon a first PCR procedure, and the function conferring nucleic acid pairs are adapted to add the functional polynucleotide sequences to the target sequence upon a second PCR procedure (Shi et al. teach a reaction mixture that contains oligonucleotides 1-9 which contain the promoter, a Shine/Dalgarno sequence, signal peptide, sequence encoding a peptide linker and terminator (= nucleic acid regions that confer function), therefore joining the function-conferring fragments to fragments  $V_H$  and  $V_L$  (Fig. 1; page 46, last paragraph; page 47, first

Art Unit: 1637

paragraph; Table 2; page 49, third paragraph). The limitation following "wherein" is an intended use limitation, therefore they do not impose structural limitation upon the claimed product.).

Regarding claims 31-33, Shi et al. teach a reaction mixture comprising Taq polymerase (page 49, fourth paragraph).

Regarding claim 34, Shi et al. teach a reaction mixture comprising an oligonucleotide which comprises a promoter (page 49, third paragraph).

Regarding claim 46, Shi et al. teach a reaction mixture comprising an oligonucleotide which comprises a terminator (page 49, third paragraph).

***Claim Rejections - 35 USC § 103***

10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

11. Claims 3, 23 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shi et al. (PCR Meth. Appl., vol. 3, pp. 46-53, 1993; cited in the previous office action) and Felgner et al. (U. S. Patent No. 6,165,720; cited in the IDS and in the previous office action).

A) The teachings of Shi et al. are described above. Shi et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach insertion of a PNA-binding domain.

B) Regarding claims 3, 23 and 35, Felgner et al. teach construction of nucleic acid vectors (or plasmids) containing PNA-binding sites (col. 12, lines 46-67; col. 13, lines 1-26; col. 26, lines 64-67; col. 27, 28; Fig. 8). The PNA-binding sites confer the following properties onto the plasmids: increased transfection efficiency, nuclear localization, transcription activation, endosomal lytic activity and immunostimulatory activity (col. 6, lines 29-47).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have added PNA-binding sites of Felgner et al. to transcriptionally-active nucleic acids of Shi et al. The motivation to do so, provided by Felgner et al. would have been that binding of PNA clamps to PNA-binding sites provided nuclease resistance to DNA duplexes (col. 6, lines 48-54).

12. Claims 7, 8, 24, 25, 36 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shi et al. (PCR Meth. Appl., vol. 3, pp. 46-53, 1993; cited in the previous office action) and Uhlman et al. (U. S. Patent No. 6,063,571; cited in the previous office action).

A) The teachings of Shi et al. are described above. Shi et al. teach addition of promoter and terminator to a nucleic acid fragment, but do not teach PNA molecules which confer nuclease resistance.

C) regarding claims 7, 8, 24, 25, 36 and 37, Uhlman et al. teach amplification of nucleic acids with DNA/PNA primers, which contain a PNA moiety at the 5' end of the primer. Such primers can be used with temperature-stable polymerases (col. 2, lines 30-49; col. 5, lines 8-46). Uhlman et al. teach that nucleic acid fragments amplified with DNA/PNA primers are resistant to exonucleases (col. 1, lines 32-39).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the DNA/PNA primers of Uhlman et al. in the amplification method of Shi et al. The motivation to do so, provided by Uhlman et al., would have been that PNA confers nuclease resistance to a DNA attached to it (col. 1, lines 32-39).

13. Claims 38, 39, 41 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shi et al. (PCR Meth. Appl., vol. 3, pp. 46-53, 1993; cited in the previous office action) and Mullis et al. (U.S. Patent No. 4,965,188; cited in the previous office action).

A) Regarding claim 38, Shi et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Shi et al. teach synthesis of human Lym-1 antibody gene by PCR from fourteen oligonucleotide fragments (page 46, fifth paragraph; page 47, first paragraph; Fig. 1). The two main fragments contained amplified  $V_H$  and  $V_L$  regions of the Lym-1 antibody, which were 615 or 522 bp and 422 bp in size, respectively (page 46, fifth paragraph; page 47, third and fourth paragraphs; Fig. 1; page 50, second paragraph). Therefore, the  $V_H$  and  $V_L$  fragments were the targets for amplification (Fig. 1). In the first step of PCR, the two fragments were contacted with primers 1-9 (page 49, third paragraph; Fig. 1). As can be seen from Fig. 1, primers 7 and 9 add to the  $V_H$  fragment first and second regions of complementarity, which are complementary to regions of primers 8 and 10, primers 5 and 8 add to the  $V_L$  fragment first and second regions of complementarity, which are complementary to regions of primers 7 and 6, etc. Therefore, at any point during the amplification reaction, each fragment, is contacted sequentially with two primers, both of which contain regions of complementarity to which the next two primers anneal.);

performing a first PCR amplification step comprising amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second

Art Unit: 1637

extension regions (Shi et al. teach PCR amplifying the  $V_H$  and  $V_L$  target fragments with fragments 1-9, which are equivalent (Fig. 1; page 829, second paragraph).);

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein one or both of the third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Shi et al. teach contacting the intermediate products, for example, products of amplification of the  $V_H$  and  $V_L$  targets with primers 1-9, which contain a promoter, a Shine/Dalgarno sequence, signal peptide, sequence encoding a peptide linker and terminator (= transcriptionally functional region), therefore joining the function-conferring fragments to fragments  $V_H$  and  $V_L$  (Fig. 1; page 46, last paragraph; page 47, first paragraph; Table 2; page 49, third paragraph).); and

performing a second PCR amplification step comprising amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises one or more functional nucleic acid regions joined to the polynucleotide target sequence (Shi et al. teach PCR amplifying the gene with fragments 2 and 10, producing a transcriptionally active product (Fig. 1; page 49, fourth paragraph; Fig. 5).).

Regarding claim 39, Shi et al. teach a transcriptional functional region being a promoter or a terminator and addition of both to the final gene sequence (Fig. 1; page 46, last paragraph; page 47, first paragraph; page 49, third and fourth paragraph).

Regarding claim 43, Shi et al. teach amplification using a Vent or Taq polymerase (page 49, fourth paragraph).

B) Shi et al. do not teach amplification of more than one target nucleic acid or separate amplification of different targets.

C) Regarding claim 38, Mullis et al. teach that in polymerase chain reaction more than one target nucleic acid can be amplified using primers specific for each target (col. 3, lines 1-67; col. 4, lines 1-5; col. 13, lines 20-30). The primers may have sequences non-complementary to the target attached at the 5' end of the primers, and the non-complementary sequences may contain promoters, linkers, coding sequences, etc. (col. 6, lines 44-53; col. 19, lines 60-67; col. 20, lines 1-6).

Regarding claim 41, Mullis et al. teach amplification of different target nucleic acids in separate tubes (col. 34, lines 57).

It would have been *prima facie* obvious to one of ordinary skill in the art to have amplified more than one target nucleic acid according to Mullis et al. in the method of gene synthesis of Shi et al. The motivation to do so, provided by Mullis et al., was that multiple nucleic acids are produced in large quantities (col. 9, lines 36-41).

14. Claims 44 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shi et al. (PCR Meth. Appl., vol. 3, pp. 46-53, 1993; cited in the previous office action) and Uhlman et al. (U. S. Patent No. 6,063,571; cited in the previous office action).

Regarding claim 44, Shi et al. teach a method of adding a nucleic acid sequence that confers function to a polynucleotide target sequence, the method comprising:

contacting first and second nucleic acid fragments with a polynucleotide target sequence, wherein the first nucleic acid fragment comprises a first region of complementarity to a portion of the polynucleotide target sequence and a first extension region, and the second nucleic acid fragment comprises a second region of complementarity to a portion of the polynucleotide target sequence and a second extension region (Shi et al. teach synthesis of human Lym-1 antibody gene by PCR from fourteen oligonucleotide fragments (page 46, fifth paragraph; page 47, first paragraph; Fig. 1). The two main fragments contained amplified V<sub>H</sub> and V<sub>L</sub> regions of the Lym-1 antibody,



Art Unit: 1637

which were 615 or 522 bp and 422 bp in size, respectively (page 46, fifth paragraph; page 47, third and fourth paragraphs; Fig. 1; page 50, second paragraph). Therefore, the  $V_H$  and  $V_L$  fragments were the targets for amplification (Fig. 1). In the first step of PCR, the two fragments were contacted with primers 1-9 (page 49, third paragraph; Fig. 1). As can be seen from Fig. 1, primers 7 and 9 add to the  $V_H$  fragment first and second regions of complementarity, which are complementary to regions of primers 8 and 10, primers 5 and 8 add to the  $V_L$  fragment first and second regions of complementarity, which are complementary to regions of primers 7 and 6, etc. Therefore, at any point during the amplification reaction, each fragment, is contacted sequentially with two primers, both of which contain regions of complementarity to which the next two primers anneal.);

performing a first PCR amplification step comprising amplifying the first and second nucleic acid fragments and the polynucleotide target sequence, to form an intermediate nucleic acid fragment that comprises the polynucleotide target sequence flanked by the first and second extension regions (Shi et al. teach PCR amplifying the  $V_H$  and  $V_L$  target fragments with fragments 1-9, which are equivalent (Fig. 1; page 829, second paragraph).);

contacting the intermediate nucleic acid fragment with a third and fourth nucleic acid fragments that respectively comprises a region complementary to the first and second extension regions, wherein each of the third and fourth nucleic acid fragments further comprise at least one nucleic acid region that confers function (Shi et al. teach contacting the intermediate products, for example, products of amplification of the  $V_H$  and  $V_L$  targets with primers 1-9, which contain a promoter, a Shine/Dalgarno sequence, a signal peptide sequence, a sequence encoding a peptide and a terminator (= transcriptionally functional region) (page 46, last paragraph; page 47, first paragraph; Table 2; page 49, third paragraph; Fig. 1.)); and

performing a second PCR amplification step comprising amplifying the intermediate nucleic acid fragment with the third and fourth nucleic acid fragments to form a product nucleic acid fragment that comprises one or more functional nucleic acid regions joined to the polynucleotide target sequence (Shi et al. teach PCR amplifying the gene with fragments 2 and 10, producing a transcriptionally active product (Fig. 1; page 49, fourth paragraph; Fig. 5).).

B) Shi et al. teach addition of transcriptionally functional regions to a nucleic acid fragment, but do not teach PNA molecules which confer nuclease resistance.

C) Regarding claims 44 and 45, Uhlman et al. teach amplification of nucleic acids with DNA/PNA primers, which contain a PNA moiety at the 5' end of the primer. Such primers can be used with temperature-stable polymerases (col. 2, lines 30-49; col. 5, lines 8-46). Uhlman et al. teach that nucleic acid fragments amplified with DNA/PNA primers are resistant to exonucleases (col. 1, lines 32-39).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the DNA/PNA primers of Uhlman et al. in the amplification method of Shi et al. The motivation to do so, provided by Uhlman et al., would have been that PNA confers nuclease resistance to a DNA attached to it (col. 1, lines 32-39).

15. No claims are allowed.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E. Strzelecka whose telephone number is (571) 272-0789. The examiner can normally be reached on M-F (8:30-5:30).

Art Unit: 1637

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

June 7, 2005

**TERESA STRZELECKA**  
**PATENT EXAMINER**  
*Teresa Strzelecka*